Cerebral amyloid angiopathy in patients with Dementia with Lewy Bodies: A clinical and hippocampal morphology study
- PMID: 40479839
- DOI: 10.1016/j.parkreldis.2025.107892
Cerebral amyloid angiopathy in patients with Dementia with Lewy Bodies: A clinical and hippocampal morphology study
Abstract
Introduction: Dementia with Lewy Bodies (DLB) is often associated with Cerebral Amyloid Angiopathy (CAA) based on pathological studies. Current literature in DLB reveals heterogenous findings regarding CAA effects on cognition, but overall suggests a diffuse impact on different cognitive domains, depending in parts on CAA severity. Reduced hippocampal volumes have also been reported in CAA patients. This study aims first at reporting the prevalence of CAA in DLB according to the Boston Criteria 2.0, and second at analyzing the impact of CAA on neuropsychological performances and hippocampal volumes in DLB patients.
Method: We retrospectively evaluated the prevalence of CAA in DLB patients followed at the Leenaards Memory Center (Lausanne University Hospital, Lausanne, Switzerland) with the Boston Criteria version 2.0 and compared cognitive performance and hippocampal volumes between DLB+CAA and DLB-CAA patients.
Results: 87 DLB patients (77.5 ± 7.2yo; 34.5 % females) were included. We found that 65.5 % of DLB patients presented with any (probable + possible) CAA. Cognitive performances and hippocampal volumes (total and segmentation) were similar between both groups.
Conclusion: This study shows that the presence of CAA does not impact cognition and hippocampal volume in patients with DLB.
Copyright © 2025 The Authors. Published by Elsevier Ltd.. All rights reserved.
Conflict of interest statement
Declaration of competing interest The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: Caroline Hall reports financial support was provided by The Anna & André Livio-Glauser Foundation, Lausanne, Switzerland. Caroline Hall, Gilles Allali reports financial support was provided by The Faculty of Biology and Medicine, University of Lausanne, Lausanne, Switzerland (Solis grant, 2022). Gilles Allali reports financial support was provided by The Leenaards Foundation, Lausanne, Switzerland. Gilles Allali reports financial support was provided by Empiris Foundation, Zurich, Switzerland. Gilles Allali reports financial support was provided by Marina Cuennet-Mauvernay Foundation, Ecublens, Switzerland. Giulia Bommarito reports financial support was provided by The Faculty of Biology and Medicine, University of Lausanne, Lausanne, Switzerland (transition grant). Gilles Allali reports financial support was provided by The Swiss National Science Foundation, Switzerland. Gilles Allali reports a relationship with Roche that includes: consulting or advisory. Gilles Allali reports a relationship with Eli Lilly and Company that includes: consulting or advisory and paid expert testimony. Gilles Allali reports a relationship with Schwabe Pharma that includes: paid expert testimony. Other authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
MeSH terms
LinkOut - more resources
Full Text Sources
Medical
